Alaunos Reports Preclinical ALN1003 Data Showing Effects on Insulin-Resistance-Related Biomarkers and Liver Histology in Diet-Induced Obesity Models
Alaunos Therapeutics released preclinical data for ALN1003 showing improved insulin-resistance biomarkers and reduced liver steatosis in diet-induced obesity mouse models. The data supports the company’s thesis that ALN1003 engages multiple metabolic axes, including adipose endocrine signaling and hepatic lipid accumulation, beyond simple weight loss.
Key figures
- Drug Name
- ALN1003
- Cash runway
- Q2 2026
- Nas score control
- 5
- Cash and equivalents
- 354000
- Nas score treated 18day
- 1.3
- Nas score treated 48day
- 2.7
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.